Celosia wins $1.35M NSW grant, largest of six, for ALS gene therapy
What's the deal? Celosia Therapeutics, a Macquarie University spinout developing gene therapies for motor neurone disease (MND), has won a US$1.29M (≈$1.35 million) grant from the NSW Government — the largest of six awards in the first round of its Emerging Technology Commercialisation Fund.
The details: The fund, backed by the nsw emerging technology commercialisation fund, distributed about $7 million across six startups chosen from 251 applicants. Celosia was the only recipient to take the maximum grant.
What's the company building? Celosia's lead program, CTx1000, is a gene therapy for sporadic amyotrophic lateral sclerosis (ALS), the most common form of MND. It targets a protein called TDP-43, which forms toxic clumps inside nerve cells in roughly 97% of ALS cases.
What's the money for? The grant funds expansion of Celosia's MND pipeline, including candidate development, manufacturing, and preclinical studies. The company will work with the NSW Viral Vector Manufacturing Facility over two years to produce the therapy reliably at larger volumes.
Why it matters: Celosia has already moved beyond the lab. In March 2026 it dosed the first participant in a Phase 1b trial testing the safety and tolerability of a single dose of CTx1000.
The backstory: The biotech grew out of research by Macquarie University professors Lars Ittner and Yazi Ke. It previously raised $16.75 million in a 2024 Series A led by UniseedDealroom has a profile for this one. Try Dealroom →, making the state award added support for clinical development rather than a fresh venture round.
The signal: The grant reflects public backing of a high-risk, research-derived therapy at an early clinical stage. The Phase 1b trial remains exploratory, and the funding is not evidence that CTx1000 works.
Read more: startupdaily.net
Image credit: Generated with Gemini